First-of-Its-Kind Wearable, Non-Invasive and Needle-Free Device Monitors Glucose Levels in Sweat
|
By LabMedica International staff writers Posted on 18 Oct 2021 |

Researchers have developed a prototype of a wearable, non-invasive glucose sensor to be worn on the arm that could make less intrusive glucose monitoring the norm.
The first-of-its-kind wearable, non-invasive low-cost sensor developed by researchers at Penn State (University Park, Pa.) can detect glucose in sweat. Non-invasive glucose monitoring devices are not currently commercially available in the US, so people with diabetes must collect blood samples or use sensors embedded under the skin to measure their blood sugar levels. The researchers constructed the device first with laser-induced graphene (LIG), a material consisting of atom-thick carbon layers in various shapes. With high electrical conductivity and a convenient fabrication time of just seconds, LIG appeared to be an ideal framework for the sensing device - but there was a significant caveat.
The team chose nickel because of its robust glucose sensitivity and combined it with gold to lower potential risks of an allergic reaction. The researchers hypothesized that the LIG outfitted with the nickel-gold alloy would be able to detect low concentrations of glucose in sweat on the skin’s surface. A material with high glucose sensitivity was a priority. Sweat exhibits remarkably low glucose concentrations compared to blood, although there is a strong correlation between glucose levels in sweat and blood. While the concentration of glucose in sweat is about 100 times less than the concentration in blood, the team’s device is sensitive enough to accurately measure the glucose in sweat and reflect the concentration in blood.
The nickel-gold alloy’s sensitivity allowed the team to exclude enzymes, which are often used to measure glucose in more invasive, commercially available devices or in non-invasive monitors proposed by other researchers. These enzymes, however, can degrade quickly with time and changing temperatures. Non-enzymatic sensors require alkaline solution, which can damage the skin and typically limits device wearability. To curb this issue, the researchers attached a microfluidic chamber to the LIG alloy. This chamber is smaller than previously developed configurations to promote wearability and porous to allow for a range of movement, such as stretching or crushing. It is connected to a collection inlet that passes sweat into the solution without allowing the solution to touch the skin. The basic solution interacts with the glucose molecules to produce a compound that reacts with the alloy. This reaction triggers an electrical signal, indicating the concentration of glucose in the sweat.
With a smaller alkaline solution chamber, the entire device is roughly the size of a quarter and is flexible enough to maintain a secure attachment to the human body. In a proof-of-concept test, the researchers used a skin-safe adhesive to attach the reusable device to a person’s arm one hour and three hours after a meal. The subject performed a brief workout - just enough to produce sweat - right before each measurement time. A few minutes after collecting the sweat, the researchers found that the detected glucose concentration dropped from the first measurement to the next. The glucose measurements from the device were verified by measurements made with a commercially available glucose monitor.
The researchers now plan to improve upon their prototype for future applications, including addressing how patients or clinicians may use the sensor for incremental glucose measurements or continuous monitoring to determine treatment actions, such as administering insulin. They also intend to refine and expand this platform for more comfortable monitoring of other biomarkers that can be found in the sweat or interstitial fluids that fill the space between cells in the body.
“We want to work with physicians and other health care providers to see how we can apply this technology for daily monitoring of a patient,” said Huanyu “Larry” Cheng, Dorothy Quiggle Career Development Professor in Penn State's Department of Engineering Science and Mechanics, who led the study. “This glucose sensor serves as a foundational example to show that we can improve the detection of biomarkers in sweat at extremely low concentrations.”
Related Links:
Penn State
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







